Pegaptanib: The first antiangiogenic agent approved for neovascular macular degeneration

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 8, 2005, Pages 1421-1423

  Doggrell, Sheila A ^a  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

Age related macular degeneration; Antiangiogenesis; Clinical trial; Neovascularisation; Pegaptanib; Vascular endothelial growth factor

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; APTAMER; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ANTERIOR EYE CHAMBER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; EYE DISEASE; HUMAN; INDUSTRIALIZATION; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS OPACITY;

ANGIOGENESIS INHIBITORS; ANIMALS; APTAMERS, NUCLEOTIDE; HUMANS; MACULAR DEGENERATION; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 22744446011     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.8.1421     Document Type: Article

References (5)

1. VAN WIJINGARDEN P, COSTER DJ, WILLIAMS KI et al.: Inhibitors of ocular neovascularization - promises and potential problems. JAMA (2005) 293:1509-1513.
2. 165). J. Biol. Chem. (1998) 32:20556-20567.
3. GRAGOUNDAS ES, ADAMIS AP, CUNNINGHAM ET et al.: Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. (2004) 351:2805-2816.
4. DOGGRELL SA: Which drug combination for colorectal cancer? Expert Opin. Pharmacother. (2004) 5:2621-2624.
5. FARHADI MR, CAPELLE HH, ERGER R, ULLRICH A, VAJKOCZY P: Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signalling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. J. Neurosurg. (2005) 102:363-370.